Earth Science Tech Inc. (ETST) Is ‘One to Watch’

• Earth Science Tech operates a diversified, revenue-generating holding company model with core exposure to pharmaceutical compounding and telemedicine markets.
• The company has demonstrated operational execution through asset growth, profitability, and disciplined share reduction initiatives.
• Regulatory alignment, including SIC 2834 pharmaceutical classification and FINRA Form 211 clearance, enhances transparency and market credibility.
• A multi-subsidiary structure provides organizational flexibility across pharmaceutical, telemedicine, healthcare, real estate, and consumer operating businesses.
• The company is led by an executive team with experience across operations, finance, technology, and strategic management, providing continuity and oversight across its operating platforms.

Earth Science Tech (OTC: ETST) is a strategic holding company that builds value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets. The company focuses on controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling can drive durable growth.

Since 2022, Earth Science Tech has completed a deliberate transition away from legacy activities and repositioned the organization around healthcare and pharmaceutical operations. That shift has been supported by regulatory alignment, expanding operating capabilities, and the assembly of a diversified portfolio of revenue-generating businesses.

Today, the company’s approach emphasizes execution, capital discipline, and long-term value creation across its operating platforms, with a focus on scaling businesses that can grow sustainably while enhancing shareholder value.

The company is headquartered in Miami, Florida.

Subsidiaries

Earth Science Tech conducts its operations through a portfolio of wholly owned and majority-owned subsidiaries spanning pharmaceutical compounding, telemedicine, healthcare services, real estate development, and direct-to-consumer products.

• RxCompoundStore.com LLC – A fully licensed compounding pharmacy based in Miami, Florida, authorized to fulfill prescriptions across more than 20 U.S. states and Puerto Rico, with ongoing licensure expansion efforts nationwide.
• Mister Meds LLC – A Texas-based compounding pharmacy operating from a 5,000-square-foot facility with advanced sterile and hazardous drug compounding capabilities, acquired to expand production capacity and geographic reach.
• Peaks Curative LLC – A telemedicine referral platform providing asynchronous consultations for Peaks-branded compounded medications, supported by an expanding provider network and recent entry into the veterinary market through Zoolzy.com.
• DOConsultations LLC – An online telehealth platform focused on customized medication formulations, supporting direct-to-patient delivery through partner pharmacies.
• Las Villas Health Care Inc. – A brick-and-mortar and telehealth healthcare provider serving the Spanish-speaking community, offering specialized wellness and sexual health services.
• Avenvi LLC – A diversified real estate development and asset management company overseeing property investments, development projects, and the company’s ongoing share repurchase program.
• MagneChef (80% interest) – A direct-to-consumer retail brand leveraging proprietary intellectual property to develop and market kitchen and cooking-related products, with recent expansion into premium American-made BBQ tools.
• Earth Science Foundation Inc. – A 501(c)(3) nonprofit organization serving as the company’s charitable arm, providing financial assistance for prescription costs to qualified individuals.

Collectively, these subsidiaries provide Earth Science Tech with diversified exposure across regulated healthcare services, digital health platforms, real estate assets, and proprietary consumer brands.

Market Opportunity

Earth Science Tech is primarily positioned within the pharmaceutical compounding and telemedicine markets, both of which are experiencing sustained growth driven by demand for personalized healthcare solutions, expanded access to care, and increasing adoption of remote service models.

The pharmaceutical compounding market continues to benefit from rising demand for customized medications, improved patient adherence, and supply-chain flexibility. According to Grand View Research, the global compounding pharmacies market was valued at approximately $13.1 billion in 2023 and is projected to reach $18.6 billion by 2030, representing a compound annual growth rate of 5.11% from 2024 to 2030. Earth Science Tech’s compounding operations through RxCompoundStore.com and Mister Meds align directly with this expanding market segment.

Telemedicine represents a second core growth vertical for the company, supporting the clinical delivery of pharmaceutical products and healthcare services. According to Fortune Business Insights, the global telemedicine market was valued at $111.99 billion in 2025 and is projected to grow to $532.08 billion by 2034, reflecting a compound annual growth rate of 20.0%, with North America accounting for approximately 48% of market share in 2025. Platforms operated by Peaks Curative and DOConsultations participate directly in this rapidly expanding digital health ecosystem.

Additional exposure to specialty healthcare clinics and real estate development provides diversification alongside the company’s core pharmaceutical and telemedicine operations.

Leadership Team

Giorgio R. Saumat, Chief Executive Officer and Chairman of the Board, is an investor and entrepreneur with more than 20 years of experience investing in, operating, and advising private businesses, including founding CASAU Group, a private equity firm focused on real estate, and POINT96 Consulting, which provides strategic planning services to businesses and accredited investors.

Ernesto L. Flores, Chief Financial Officer, is a financial executive with over a decade of experience in accounting, taxation, and financial management, having held senior roles overseeing compliance and financial operations at logistics and investment firms.

Mario G. Tabraue, President and Chief Operating Officer, brings experience across real estate, maritime operations, and digital infrastructure and was instrumental in acquiring RxCompoundStore.com with the vision of scaling it into a nationally competitive pharmaceutical and telemedicine platform.

Christopher Rose, Chief Technology Officer, is a technology and automation executive who previously led enterprise-wide automation initiatives at a Fortune 100 company, delivering large-scale operational efficiencies and global process automation.

For more information, visit the company’s website at https://earthsciencetech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN